Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy

Cancer Letters

Volumn 375, Issue 2, 2016, Pages 349-359

  Wang, Huan Huan ^a   Cui, Yao Li ^a   Zaorsky, Nicholas G ^b   Lan, Jie ^c   Deng, Lei ^c   Zeng, Xian Liang ^a   Wu, Zhi Qiang ^a   Tao, Zhen ^a   Guo, Wen Hao ^c   Wang, Qing Xin ^a   Zhao, Lu Jun ^a   Yuan, Zhi Yong ^a   Lu, You ^c   Wang, Ping ^a   Meng, Mao Bin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b FOX CHASE CANCER CENTER   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Mesenchymal stem cells; Pericytes; Stereotactic body radiation therapy; Tumor recurrence; Vasculogenesis

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GREEN FLUORESCENT PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MARROW TRANSPLANTATION; CANCER INHIBITION; CELL DIFFERENTIATION; CELL HOMING; CELL MATURATION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MELANOMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RADIATION DOSE FRACTIONATION; STEM CELL CULTURE; STEREOTACTIC BODY RADIATION THERAPY; TRANSGENIC MOUSE; TUMOR CELL; TUMOR RECURRENCE; ADVERSE EFFECTS; ANIMAL; CARCINOMA, LEWIS LUNG; CELL MOTION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; RADIATION RESPONSE; RADIOSURGERY; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL DIFFERENTIATION; CELL MOVEMENT; GREEN FLUORESCENT PROTEINS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, TRANSGENIC; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; RADIOSURGERY; TUMOR MICROENVIRONMENT;

EID: 84962599677     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.033     Document Type: Article

References (61)

1. Tyldesley S., Boyd C., Schiclze K., Walker H., Mackillop W.J. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int. J. Radiat. Oncol. Biol. Phys 2001, 49:973-985.
2. Chi A., Liao Z., Nguyen N.P., Xu J., Stea B., Komaki R. Systematic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implication. Radiother. Oncol 2010, 94:1-11.
3. Koto M., Takai Y., Ogawa Y., Matsushita H., Takeda K., Takahashi C., et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother. Oncol 2007, 85:429-434.
4. Stereotactic body radiation therapy in treating patients with inoperable stage I or stage II non-small cell lung cancer Radiation Therapy Oncology Group 0236. http://www.clinicaltrial.gov.
5. Jain R.K. A new target for tumor therapy. N. Engl. J. Med 2009, 360:2669-2671.
6. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov 2007, 6:273-286.
7. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest 2010, 120:694-705.
8. Martin B.J. Inhibiting vasculogenesis after radiation: a new paradigm to improve local control by radiotherapy. Semin. Radiat. Oncol 2013, 23:281-287.
9. Brown J.M. Vasculogenesis: a crucial player in the resistance of solid tumors to radiotherapy. Br. J. Radiol 2014, 87. 20130686.
10. Michael A., Matus S., Frank C.M., Richard C., Claudia Z., Isaiah J.F. Bone marrow derived mesenchymal stem cells serve as precursors for stromal fibroblasts in malignant tumors and show potential for cancer therapy. Blood 2001, 9:697a.
11. Zhang Y., Daquinag A., Traktuev D.O., Amaya-Manzanares F., Simmons P.J., March K.L., et al. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res 2009, 69:5259-5266.
12. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
13. Morigi M., Imberti B., Zoja C., Corna D., Tomasoni S., Abbate M., et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J. Am. Soc. Nephrol 2004, 15:1794-17804.
14. Li H., Fu X., Ouyang Y., Cai C., Wang J., Sun T. Adult bone-marrow-derived mesenchymal stem cells contribute to wound healing of skin appendages. Cell Tissue Res 2006, 326:725-736.
15. Kidd S., Spaeth E., Watson K., Burks J., Lu H., Klopp A., et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE 2012, 7:e30563.
16. Francois S., Bensidhoum M., Mouiseddine M., Mazurier C., Allenet B., Semont A., et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 2006, 24:1020-1029.
17. Klopp A.H., Spaeth E.L., Dembinski J.L., Woodward W.A., Munshi A., Meyn R.E., et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007, 67:11687-11695.
18. Zielske S.P., Livant D.L., Lawrence T.S. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int. J. Radiat. Oncol. Biol. Phys 2009, 75:843-853.
19. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins, identification by morphologic and immunologic criteria. J. Clin. Invest 1973, 52:2745-2756.
20. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFRβ+ perivascular progenitor cells in tumors regulates pericyte differentiation and vascular survival. Nat. Cell Biol 2005, 7:870-879.
21. Fazel S., Cimini M., Chen L., Li S., Angoulvant D., Fedak P., et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest 2006, 116:1865-1877.
22. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol 2013, 31:2205-2218.
23. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
24. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009, 4:e4992.
25. Muehlberg F.L., Song Y.H., Krohn A., Pinilla S.P., Droll L.H., Leng X., et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 2009, 30:589-597.
26. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:1-4.
27. Pittenger M.F., Mosca J.D., McLntosh K.R. Human mesenchymal stem cells: progenitor cells for cartilage, bone, fat and stroma. Curr. Top. Microbiol. Immunol 2000, 251:3-11.
28. Mishra P.J., Mishra P.J., Glod J.W., Banerjee D. Mesenchymal stem cells: flip side of the coin. Cancer Res 2009, 69:1255-1258.
29. Klopp A.H., Gupta A., Spaeth E., Andreeff M., Marini F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells 2011, 29:11-19.
30. Liu R., Wei S., Chen J., Xu S. Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Lett 2014, 353:145-152.
31. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
32. Schmidt A., Ladage D., Schinkothe T., Klausmann U., Ulrichs C., Klinz F.J., et al. Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells 2006, 24:1750-1758.
33. Ringe J., Strassburg S., Neumann K., Endres M., Notter M., Burmester G.R., et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J. Cell. Biochem 2007, 101:135-146.
34. Ries C., Egea V., Karow M., Kolb H., Jochum M., Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007, 109:4055-4063.
35. Gorski D.H., Bechett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374-3378.
36. Li M., Jendrossek V., Belka C. The role of PDGF in radiation oncology. Radiat. Oncol 2007, 2:5.
37. Meng M.B., Jiang X.D., Deng L., Na F.F., He J.Z., Xue J.X., et al. Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence. Radiother. Oncol 2013, 106:130-137.
38. Lan J., Wan X.L., Deng L., Xue J.X., Wang L.S., Meng M.B., et al. Ablative hypofractionated radiotherapy normalizes tumor vasculature in Lewis lung carcinoma mice model. Radiat. Res 2013, 179:458-464.
39. Zhou Z., Stewart K.S., Yu L., Kleinerman E.S. Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung. Angiogenesis 2011, 14:125-133.
40. Wen Q.L., Meng M.B., Yang B., Tu L.L., Jia L., Zhou L., et al. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 2009, 100:1510-1519.
41. Chen F.H., Chiang C.S., Wang C.C., Tsai C.S., Jung S.M., Lee C.C., et al. Radiotherapy decreases vascular density and cause hypoxia with macrophage aggregation in tramp-c1 prostate tumors. Clin. Cancer Res 2009, 15:1721-1729.
42. Rajantie I., Iimonent M., Alminaite A., Ozerdem U., Alitalo K., Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004, 104:2084-2086.
43. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., et al. HIF-1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
44. Valarmathi M.T., Davis J.M., Yost M., Goodwin R., Potts J. A three-dimensional model of vasculogenesis. Biomaterials 2009, 1-15.
45. Khan W.S., Adesida A.B., Tew S.R., Lowe E.T., Hardingham T.E. Bone marrow-derived mesenchymal stem cells express the pericyte marker 3G5 in culture and show enhanced chondrogenesis in hypoxic conditions. J. Orthop. Res 2010, 28:834-840.
46. Caplan A.I. All MSCs are pericytes?. Cell Stem Cell 2008, 3:229-230.
47. Meng M.B., Zaorsky N.G., Deng L., Wang H.H., Chao J., Zhao L.J., et al. Pericytes: a double-edged sword in cancer therapy. Future Oncol 2015, 11:169-179.
48. Handan R., Zhou Z., Kleinerman E.S. SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes. Mol. Cancer Res 2011, 9:1462-1470.
49. Handan R., Zhou Z., Kleinerman E.S., Blocking S.D.F. 1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Mol. Cancer Ther 2014, 13:483-491.
50. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest 2003, 111:1287-1295.
51. von Tell D., Armulik A., Betsholtz C. Pericytes and vascular stability. Exp. Cell Res 2006, 312:623-629.
52. Caplan A.I. Why are MSCs therapeutic? New data: new insight. J. Pathol 2009, 217:318-324.
53. Melero-Martin J.M., De Obaldia M.E., Kang S.Y., Khan Z.A., Yuan L., Oettgen P., et al. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ. Res 2008, 103:194-202.
54. Cai X., Lin Y., Friedrich C.C., Neville C., Pomerantseva I., Sundback C.A., et al. Bone marrow derived pluripotent cells are pericytes which contribute to vascularization. Stem Cell Rev 2009, 5:437-445.
55. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
56. Bexell D., Gunnarsson S., Tormin A., Darabi A., Gisselsson D., Roybon L., et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol. Ther 2009, 17:183-190.
57. Dhar K., Dhar G., Majumder M., Haque I., Mehta S., Van Veldhuizen P.J., et al. Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1. Mol. Cancer 2010, 9:209.
58. Nakagaki S., Arimura Y., Nagaishi K., Isshiki H., Nasuno M., Watanabe S., et al. Contextual niche signals towards colorectal tumor progression by mesenchymal stem cell in the mouse xenograft model. J. Gastroenterol 2015, 50:962-974.
59. Klein D., Meissner N., Kleff V., Jastrow H., Yamaguchi M., Ergün S., et al. Nestin (+) tissue-resident multipotent stem cells contribute to tumor progression by differentiating into pericytes and smooth muscle cells resulting in blood vessel remodeling. Front. Oncol 2014, 4:169.
60. Cheng L., Huang Z., Zhou W., Wu Q., Donnola S., Liu J.K., et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013, 153:139-152.
61. Armulik A., Genove G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011, 21:193-215.